Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Profit After Tax: 2009-2025

Historic Profit After Tax for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to -$1.9 million.

  • Cumberland Pharmaceuticals' Profit After Tax fell 26.23% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 69.38%. This contributed to the annual value of -$6.5 million for FY2024, which is 2.35% down from last year.
  • Cumberland Pharmaceuticals' Profit After Tax amounted to -$1.9 million in Q3 2025, which was down 163.12% from -$740,740 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Profit After Tax registered a high of $1.3 million during Q1 2025, and its lowest value of -$6.3 million during Q4 2023.
  • For the 3-year period, Cumberland Pharmaceuticals' Profit After Tax averaged around -$1.3 million, with its median value being -$1.1 million (2024).
  • In the last 5 years, Cumberland Pharmaceuticals' Profit After Tax surged by 173.16% in 2021 and then tumbled by 1,112.71% in 2024.
  • Cumberland Pharmaceuticals' Profit After Tax (Quarterly) stood at -$4.4 million in 2021, then spiked by 43.94% to -$2.5 million in 2022, then plummeted by 156.21% to -$6.3 million in 2023, then soared by 69.79% to -$1.9 million in 2024, then dropped by 26.23% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$740,740 for Q2 2025, and $1.3 million during Q1 2025.